A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

Frailty status was measured in relation to the accumulation of deficits using a Frailty Index (FI) adapted from the model proposed by Mitnitski et al. \[Mitnitski, 2001\]. The different aspects of frailty composing the FI were assessed through the medical history and components of the Short Form 36 Questionnaire (SF-36) and EuroQol (EQ)-5D questionnaires recorded pre-vaccination Dose 1 (in the study ZOSTER-006\[NCT01165177\] and ZOSTER-022\[NCT01165229\]). If the FI was less than or equal to 0.08, the subject was classified as Non-Frail. If the score was greater than 0.08 but less than or equal to 0.25, the subject was classified as pre-frail. If the score was greater than 0.25, the subject was classified as Frail. Subjects without a FI score were classified as unknown.

Time frame: At Baseline (Month 0)

Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064

Anti-gE Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 97 milli-international units (mIU)/mL.

Time frame: Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38

Population: Analysis was performed on a subset of subjects in Z-064 According to Protocol (ATP) cohort for immunogenicity-humoral (i.e. those among the Z-064 TVC, who met all eligibility criteria, complied with procedures and intervals for analysis,with no elimination criteria during Z-006/022 studies,and for whom data concerning immunogenicity were available)

Anti-VZV Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 25 mIU/mL.

Time frame: Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38

Population: Analysis was performed on a subset of subjects in Z-064 According to Protocol (ATP) cohort for immunogenicity-humoral (i.e. those among the Z-064 TVC, who met all eligibility criteria, complied with procedures and intervals for analysis,with no elimination criteria during Z-006/022 studies,and for whom data concerning immunogenicity were available)

The EQ-5D questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 possible responses (No symptoms, Moderate symptoms, Extreme symptoms). The 5 items are then combined to generate health profiles that are subsequently converted to a continuous single index utility score using a one to one matching. Country or region-specific value sets are used for the score conversion. The scores range from less than 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D also contains a visual analogue scale (VAS). The VAS records the respondent's self-rated health on a vertical scale, ranging from 0(worst imaginable health state) to 100(best imaginable health state).

Time frame: At Month 0, 14, 26 and 38

Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064

The mean and standard deviation of the SF-36 Questionnaire scale scores are presented for each time point. The SF-36 is a multi-purpose health survey with 36 questions underlying the construction of 8 scales \[Ware, 2001\]: Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH). All but one of the 36 items (self-reported health transition) are used to score the eight SF-36 scales. Each item is used in scoring only one scale. Scale scores are constructed following the summated ratings and standardized SF-36 scoring algorithms. The SF-36 scores range from 0 to 100, with high scores indicating high levels of functioning/quality of life.

Time frame: At Month 0, 14, 26 and 38

Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064

Zoster Brief Pain Inventory (ZBPI) Burden of Illness (BOI) score was calculated as the sum of the ZBPI worst pain scores for all subjects in the group divided by the total follow-up time (Person-years). HZ Burden of Illness score for subjects was calculated from the Zoster Brief Pain Inventory (ZBPI), for each confirmed HZ cases responding to the worst pain question in both ZOSTER-006 and ZOSTER-022, and defined as the area under the curve of confirmed HZ-associated pain plotted against time during the 182-day period after the onset of the case. Subjects who developed HZ presented burden-of-illness scores ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom HZ did not develop during the study period. Subjects who had a confirmed Zoster episode but who did not have at least 1 ZBPI assessment were excluded from the analysis.

Time frame: During the entire study period (3 to 5 year period following Day 0)

Population: Analysis was performed on all subjects in the Modified Total Vaccinated Cohort (mTVC) of ZOSTER-064. The Z-064 mTVC excluded subjects in the Z-064 TVC who were not administered the second vaccination or who developed a confirmed case of Herpes Zoster (HZ) prior to 1 month after the second vaccination.

Incidence rate (IR) of confirmed Herpes zoster (HZ) cases with 95% Confidence Interval (CI) calculated as the number of cases per 1000 person-years : numerator = number of confirmed HZ cases reported during the follow-up (FU) period at risk; denominator = total Person-years at risk, i.e. sum of FU periods at risk expressed in years until first confirmed HZ cases or occurrence of treatment for relapse. A suspected HZ case defined as (1) new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) clinical presentation and specific laboratory findings suggestive of VZV infection in the absence of HZ or VZV rash. A suspected case of HZ was confirmed either by PCR or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.

Time frame: During the entire study period (3 to 5 year period following Day 0)

Population: Analysis was performed on all subjects in the Modified Total Vaccinated Cohort (mTVC) of ZOSTER-064. The Z-064 mTVC excluded subjects in the Z-064 TVC who were not administered the second vaccination or who developed a confirmed case of Herpes Zoster (HZ) prior to 1 month after the second vaccination.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame: Within 7 days (Days 0-6) after each vaccination

Population: Analysis was performed on all subjects in the Zoster-064 TVC diary card subset for analysis of reactogenicity. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as related to the vaccination.

Time frame: During the entire study period (3 to 5 year period following Day 0)

Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs were those considered vaccine-related by the investigator.

Time frame: From Month 0 to Month 14

Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

Serious adverse events (SAEs) assessed include medical occurrences that result in death.

Time frame: During the entire study period (3 to 5 year period following Day 0)

Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

Assessed solicited general symptoms were, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and gastro-intestinal (GI) symptoms(nausea, vomiting, diarrhoea and/or abdominal pain) Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame: Within 7 days (Days 0-6) after each vaccination

Population: Analysis was performed on all subjects in the Zoster-064 TVC diary card subset for analysis of reactogenicity. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

An unsolicited AE covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame: Within 30 days (Days 0 - 29) after each vaccination

Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs throughout the entire study period by frailty status were reported for SAEs considered related to study participation or to a concurrent GSK medication/vaccine.

Time frame: During the entire study period (3 to 5 year period following Day 0)

Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.